Step 1 topics → Endocrine → Multiple Endocrine Neoplasia Types 2A and 2B

Multiple Endocrine Neoplasia Types 2A and 2B

USMLE Step 1 trap: Conflates MEN2A and MEN2B, missing that MEN2B has mucosal neuromas/marfanoid habitus instead of hyperparathyroidism. MEN2A includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia; MEN2B replaces parathyroid disease with mucosal neuromas and marfanoid habitus.

MEN2A and MEN2B are autosomal dominant cancer syndromes driven by activating RET mutations, and USMLE Step 1 tests this from multiple angles. Students consistently conflate MEN2A and MEN2B — both share MTC and pheochromocytoma, but MEN2A adds parathyroid hyperplasia while MEN2B adds mucosal neuromas and marfanoid habitus. The unifying feature of both is medullary thyroid carcinoma (MTC), which is what makes early genetic diagnosis and prophylactic thyroidectomy so critical. The exam also exploits the contrast with MEN1: MEN2 is a gain-of-function oncogene (RET), the opposite mechanism from MEN1's loss-of-function tumor suppressor.

The trickiest part for most students is keeping MEN2A and MEN2B straight. Both share MTC and pheochromocytoma — but that's where the overlap ends. MEN2A adds parathyroid hyperplasia; MEN2B adds mucosal neuromas and marfanoid habitus instead. A lot of students either conflate the two syndromes entirely or mix up which add-on features belong to which. The other major trap is confusing the molecular mechanism: MEN2 is a gain-of-function mutation in an oncogene (RET), not a loss-of-function in a tumor suppressor like MEN1. These are mechanistically opposite, and Step 1 exploits that contrast.

Management questions are increasingly high-yield on USMLE Step 1, especially prophylactic thyroidectomy timing. Knowing that surgery is recommended — but not knowing that timing is stratified by mutation risk category — will cost you points. MEN2B with codon 918 mutations is the most aggressive and requires thyroidectomy within the first 6 months of life. This is the kind of specific, actionable detail the exam rewards.

From real student decks
57%have cards covering this topic
35%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: MEN2A and MEN2B have identical components except for the name.
Right: MEN2A includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia; MEN2B replaces parathyroid disease with mucosal neuromas and marfanoid habitus.
MEN2A and MEN2B are not just different names for the same thing — they have distinct clinical profiles beyond their shared MTC and pheochromocytoma. MEN2A includes parathyroid hyperplasia, which causes hypercalcemia; MEN2B drops the parathyroid involvement entirely and instead presents with mucosal neuromas (bumps on the lips and tongue) and a marfanoid body habitus. On a vignette, a tall patient with long limbs, lip nodules, and a thyroid mass points to MEN2B — not MEN2A.
Common mistake
Wrong: MEN2 is caused by a tumor suppressor gene loss-of-function mutation like MEN1.
Right: MEN2 is caused by an activating (gain-of-function) mutation in the RET proto-oncogene, inherited in an autosomal dominant pattern.
MEN1 and MEN2 both cause multiple endocrine tumors but through opposite molecular mechanisms — and this is a favorite exam contrast. MEN1 involves loss of the menin tumor suppressor (two-hit model). MEN2 involves a gain-of-function activating mutation in RET, a proto-oncogene encoding a receptor tyrosine kinase — meaning a single mutant allele is enough to drive tumorigenesis. This is autosomal dominant not because a second hit is needed, but because one activated copy of RET constitutively signals for cell proliferation.
Common mistake
Gap: Missing that prophylactic thyroidectomy timing in MEN2 is stratified by specific RET mutation risk category, with MEN2B requiring surgery in infancy
Prophylactic thyroidectomy timing in MEN2 depends on the specific RET mutation: highest-risk mutations (e.g., codon 918 in MEN2B) warrant thyroidectomy within the first 6 months of life.
It's not enough to know that prophylactic thyroidectomy is recommended in MEN2 — you need to know when. Timing is risk-stratified based on the specific RET codon mutation. MEN2B mutations (especially codon 918) carry the highest risk of early aggressive MTC and require thyroidectomy within the first 6 months of life. Lower-risk mutations may allow surgery to be deferred to age 5 or based on calcitonin levels. The exam will distinguish students who know this nuance from those who just know 'thyroidectomy is done.'
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the three components of MEN2A: medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia — and that it is caused by an activating RET proto-oncogene mutation inherited in an autosomal dominant pattern.
  2. Distinguish MEN2B from MEN2A: MEN2B includes medullary thyroid carcinoma and pheochromocytoma like MEN2A, but instead of parathyroid hyperplasia it features mucosal neuromas and marfanoid habitus.
  3. Apply the principle that prophylactic thyroidectomy is the management cornerstone in MEN2, with timing stratified by specific RET mutation risk — MEN2B (codon 918) requires surgery within the first 6 months of life due to its especially aggressive MTC.

Can you avoid these mistakes?

A 16-year-old is found to have a pheochromocytoma. Genetic testing reveals a RET mutation. His father had thyroid cancer. Physical exam shows nodules on his lips and an unusually tall, slender build. Which MEN syndrome does he have, and what component is notably absent compared to the other MEN2 subtype?
A classmate says 'MEN2 must work like MEN1 — you lose both copies of a tumor suppressor.' What's wrong with this statement, and what is the correct molecular mechanism underlying MEN2?
A newborn is diagnosed with MEN2B based on a high-risk RET codon 918 mutation identified on genetic testing after a parent's diagnosis. What is the recommended management, and why does timing matter more here than in MEN2A?
You see a question stem describing a patient with hypercalcemia, elevated calcitonin, and episodic hypertension. Which MEN2 subtype fits this picture, and what is the triad of components you should immediately recall?

Related topics

Thyroid Cancers (Papillary, Follicular, Medullary, Anaplastic) Pheochromocytoma and Paraganglioma Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →